Skip to main content
. 2024 Mar 5;74(743):e355–e363. doi: 10.3399/BJGP.2023.0214

Table 1.

Baseline characteristics

Characteristic Children (N = 2512) Adolescents (N = 1511) Adults (N = 13 434)
Age, years, median (IQR) 8.9 (7.5–10.3) 14.5 (13.2–16.0) 48.9 (33.9–63.9)

Sex, female, n (%) 893 (35.5) 747 (49.4) 9624 (71.6)

Ethnicity, n (%)
White 1323 (52.7) 717 (47.5) 8893 (66.2)
Black 215 (8.6) 105 (6.9) 556 (4.1)
Mixed 136 (5.4) 79 (5.2) 265 (2.0)
Asian 403 (16.0) 200 (13.2) 1375 (10.2)
Other 57 (2.3) 23 (1.5) 167 (1.2)
Missing 378 (15.0) 387 (25.6) 2178 (16.2)

Index of Multiple Deprivation quintile, n (%)
1 (least deprived) 369 (14.7) 210 (13.9) 2044 (15.2)
2 355 (14.1) 208 (13.8) 2207 (16.4)
3 400 (15.9) 263 (17.4) 2435 (18.1)
4 555 (22.1) 336 (22.2) 3059 (22.8)
5 (most deprived) 831 (33.1) 494 (32.7) 3681 (27.4)
Missing 2 (0.1) 0 (0) 8 (0.1)

Body mass index, n (%)
Underweight 186 (7.4) 203 (13.4) 299 (2.2)
Normal weight 1008 (40.1) 633 (41.9) 3172 (23.6)
Overweight 245 (9.8) 215 (14.2) 3587 (26.7)
Obesity 122 (4.9) 139 (9.2) 5593 (41.6)
Missing 951 (37.9) 321 (21.2) 783 (5.8)

Smoking status, n (%)
Current smoker 176 (11.6) 4093 (30.5)
Former smoker 193 (12.8) 5296 (39.4)
Never smoked 921 (61.0) 3818 (28.4)
Missing 221 (14.6) 227 (1.7)

Comorbidities, n (%)
Allergies 714 (28.4) 605 (40.0) 4505 (33.5)
Atopic eczema 1392 (55.4) 871 (57.6) 4205 (31.3)
Allergic rhinitis 529 (21.1) 569 (37.7) 4344 (32.3)
Gastro-oesophageal reflux disease 162 (6.4) 76 (5.0) 2328 (17.3)
Chronic rhinosinusitis 0 (0) 3 (0.2) 425 (3.2)
Anxiety 20 (0.8) 104 (6.9) 4407 (32.8)
Depression 22 (0.9) 59 (3.9) 6432 (47.9)

Medication use within previous year, n (%)
Short-acting beta 2 agonist
  0 prescriptions 323 (12.9) 227 (15.0) 3022 (22.5)
  1–3 prescriptions 1055 (42.0) 488 (32.3) 4213 (31.4)
  4–6 prescriptions 604 (24.0) 316 (20.9) 2530 (18.8)
  ≥7 prescriptions 530 (21.1) 480 (31.8) 3669 (27.3)
Oral corticosteroid 990 (39.4) 565 (37.4) 7018 (52.2)
Inhaled corticosteroid 1973 (78.5) 1193 (79.0) 10 382 (77.3)
Long-acting beta 2 agonist 55 (2.2) 78 (5.2) 2760 (20.5)
Long-acting muscarinic antagonist 0 (0) 7 (0.5) 1206 (9.0)
Leukotriene receptor antagonist 804 (32.0) 482 (31.9) 2608 (19.4)
Flu vaccine 1025 (40.8) 564 (37.3) 6920 (51.5)

Hospital admissions, n (%)
0 2254 (89.7) 1385 (91.7) 12 865 (95.8)
1–3 237 (9.4) 98 (6.5) 469 (3.5)
4–6 14 (0.6) 7 (0.5) 41 (0.3)
≥7 7 (0.3) 21 (1.4) 59 (0.4)

IQR = interquartile range.